KR102682159B1 - 수면 무호흡을 치료하기 위한 방법 및 조성물 - Google Patents

수면 무호흡을 치료하기 위한 방법 및 조성물 Download PDF

Info

Publication number
KR102682159B1
KR102682159B1 KR1020197034523A KR20197034523A KR102682159B1 KR 102682159 B1 KR102682159 B1 KR 102682159B1 KR 1020197034523 A KR1020197034523 A KR 1020197034523A KR 20197034523 A KR20197034523 A KR 20197034523A KR 102682159 B1 KR102682159 B1 KR 102682159B1
Authority
KR
South Korea
Prior art keywords
delete delete
oxybutynin
atomoxetine
pharmaceutical composition
sleep
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197034523A
Other languages
English (en)
Korean (ko)
Other versions
KR20190140019A (ko
Inventor
디. 앤드류 웰먼
루이지 타란토-몬테무로
Original Assignee
더 브리검 앤드 우먼즈 하스피털, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63918622&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102682159(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 더 브리검 앤드 우먼즈 하스피털, 인크. filed Critical 더 브리검 앤드 우먼즈 하스피털, 인크.
Priority to KR1020247009759A priority Critical patent/KR20240042261A/ko
Publication of KR20190140019A publication Critical patent/KR20190140019A/ko
Application granted granted Critical
Publication of KR102682159B1 publication Critical patent/KR102682159B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020197034523A 2017-04-28 2018-04-26 수면 무호흡을 치료하기 위한 방법 및 조성물 Active KR102682159B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020247009759A KR20240042261A (ko) 2017-04-28 2018-04-26 수면 무호흡을 치료하기 위한 방법 및 조성물

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762491504P 2017-04-28 2017-04-28
US62/491,504 2017-04-28
US201762558814P 2017-09-14 2017-09-14
US62/558,814 2017-09-14
PCT/US2018/029518 WO2018200775A1 (en) 2017-04-28 2018-04-26 Methods and compositions for treating sleep apnea

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020247009759A Division KR20240042261A (ko) 2017-04-28 2018-04-26 수면 무호흡을 치료하기 위한 방법 및 조성물

Publications (2)

Publication Number Publication Date
KR20190140019A KR20190140019A (ko) 2019-12-18
KR102682159B1 true KR102682159B1 (ko) 2024-07-08

Family

ID=63918622

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020197034523A Active KR102682159B1 (ko) 2017-04-28 2018-04-26 수면 무호흡을 치료하기 위한 방법 및 조성물
KR1020247009759A Ceased KR20240042261A (ko) 2017-04-28 2018-04-26 수면 무호흡을 치료하기 위한 방법 및 조성물
KR1020257032249A Pending KR20250145704A (ko) 2017-04-28 2018-04-26 수면 무호흡을 치료하기 위한 방법 및 조성물

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020247009759A Ceased KR20240042261A (ko) 2017-04-28 2018-04-26 수면 무호흡을 치료하기 위한 방법 및 조성물
KR1020257032249A Pending KR20250145704A (ko) 2017-04-28 2018-04-26 수면 무호흡을 치료하기 위한 방법 및 조성물

Country Status (22)

Country Link
US (4) US11123313B2 (enExample)
EP (1) EP3615016A4 (enExample)
JP (3) JP7373997B2 (enExample)
KR (3) KR102682159B1 (enExample)
CN (2) CN110799181A (enExample)
AU (3) AU2018260666B2 (enExample)
BR (1) BR112019022483A2 (enExample)
CA (1) CA3061468A1 (enExample)
CO (1) CO2019013180A2 (enExample)
CR (1) CR20190546A (enExample)
DO (1) DOP2019000274A (enExample)
EC (1) ECSP19084058A (enExample)
GE (4) GEP20227387B (enExample)
MA (1) MA49069A (enExample)
MX (2) MX394941B (enExample)
MY (1) MY200172A (enExample)
NI (1) NI201900110A (enExample)
PH (1) PH12019502427A1 (enExample)
SG (2) SG10202111623TA (enExample)
UA (1) UA127759C2 (enExample)
WO (1) WO2018200775A1 (enExample)
ZA (1) ZA201907158B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110799181A (zh) * 2017-04-28 2020-02-14 布里格姆妇女医院 用于治疗睡眠呼吸暂停的方法和组合物
PT3746126T (pt) * 2018-01-30 2024-10-21 Apnimed Inc Delaware Métodos e composições para o tratamento de apneia do sono ou roncopatia simples
CN108309261B (zh) * 2018-02-11 2020-05-22 西安交通大学 一种猝死预警方法及装置和系统
US20190381056A1 (en) 2018-06-17 2019-12-19 Axsome Therapeutics, Inc. Compositions for delivery of reboxetine
US20200147093A1 (en) 2018-10-15 2020-05-14 Axsome Therapeutics, Inc. Use of esreboxetine to treat nervous system disorders such as fibromyalgia
US11020402B2 (en) 2018-10-15 2021-06-01 Axsome Therapeutics, Inc. Use of reboxetine to treat narcolepsy
JP2022506113A (ja) * 2018-10-31 2022-01-17 アプニメッド，インコーポレイテッド（デラウェア） 睡眠時無呼吸を治療するための方法及び組成物
PH12021551850A1 (en) * 2019-02-08 2022-05-11 Brigham & Womens Hospital Inc Methods and compositions for treating sleep apnea
WO2021091902A1 (en) * 2019-11-04 2021-05-14 Apnimed, Inc. (Delaware) Combination pharmacological interventions for multiple mechanisms of obstructive sleep apnea
JP7776442B2 (ja) 2020-05-05 2025-11-26 アプニメッド，インコーポレイテッド（デラウェア） （ｒ）－オキシブチニン塩酸塩の多形形態
CN114159568B (zh) * 2020-09-11 2025-08-01 北京原基华毅生物科技有限公司 Sik抑制剂在制备用于预防和/或治疗睡眠障碍的药物中的应用
RU2757470C1 (ru) * 2020-11-19 2021-10-18 Ренат Рашитович Ахмеров Способ лечения храпа с помощью введения тромбоцитарной аутологичной плазмы
WO2022155162A1 (en) * 2021-01-14 2022-07-21 Apnimed, Inc. (Delaware) Methods and compositions for treating sleep apnea
JP2024508498A (ja) * 2021-03-04 2024-02-27 アプニメッド，インコーポレイテッド（デラウェア） 睡眠時無呼吸の治療における使用のためのレボキセチン及びムスカリン受容体拮抗薬（ｍｒａ）の組み合わせ
EP4322930A1 (en) * 2021-04-16 2024-02-21 Apnimed, Inc. (Delaware) Combination of a norepinephrine reuptake inhibitor and a cannabinoid for use in treating sleep apnea
EP4355333A1 (en) * 2021-06-17 2024-04-24 Apnimed, Inc. (Delaware) Norepinephrine reuptake inhibitors for treating sleep apnea
US20240358709A1 (en) * 2021-08-31 2024-10-31 Apnimed, Inc. (Delaware) Methods and compositions for treating sleep apnea
EP4452242A1 (en) 2021-12-22 2024-10-30 Bayer Aktiengesellschaft Combination of an ?2-adrenoceptor subtype c (alpha-2c) antagonist with a norepinephrine reuptake inhibitor for the treatment of sleep apnea
CN118434414A (zh) 2021-12-22 2024-08-02 拜耳公司 用于治疗睡眠呼吸暂停的α2-肾上腺素受体亚型C（α-2C）拮抗剂与毒蕈碱受体拮抗剂的结合物
KR20240127384A (ko) * 2021-12-22 2024-08-22 바이엘 악티엔게젤샤프트 수면 무호흡의 치료를 위한 task1/3 채널 차단제와 노르에피네프린 재흡수 억제제의 조합물
WO2023219991A1 (en) * 2022-05-13 2023-11-16 Apnimed, Inc. (Delaware) Methods and compositions for treating sleep apnea

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020010216A1 (en) * 2000-02-24 2002-01-24 Karen Rogosky New drug combinations

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU767877B2 (en) 1999-05-20 2003-11-27 Sepracor, Inc. Methods for treatment of asthma using S-oxybutynin
WO2006023702A2 (en) * 2004-08-20 2006-03-02 Cypress Bioscience, Inc. Method for treating sleep related breathing disorders with setiptiline
CA2590802A1 (en) * 2004-12-20 2006-06-29 Collegium Pharmaceutical, Inc. Pharmaceutical compositions for sleep disorders
CN103458899A (zh) * 2011-01-28 2013-12-18 辉达斯医学研究所 治疗阻塞性睡眠呼吸暂停的方法
CN110799181A (zh) * 2017-04-28 2020-02-14 布里格姆妇女医院 用于治疗睡眠呼吸暂停的方法和组合物
PT3746126T (pt) * 2018-01-30 2024-10-21 Apnimed Inc Delaware Métodos e composições para o tratamento de apneia do sono ou roncopatia simples

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020010216A1 (en) * 2000-02-24 2002-01-24 Karen Rogosky New drug combinations

Also Published As

Publication number Publication date
US11123313B2 (en) 2021-09-21
US20210401777A1 (en) 2021-12-30
JP2020517719A (ja) 2020-06-18
MA49069A (fr) 2020-03-04
MY200172A (en) 2023-12-12
EP3615016A4 (en) 2021-02-24
KR20250145704A (ko) 2025-10-13
KR20240042261A (ko) 2024-04-01
JP2025169279A (ja) 2025-11-12
ZA201907158B (en) 2021-09-29
GEP20227387B (en) 2022-06-10
CN119185558A (zh) 2024-12-27
AU2025230729A1 (en) 2025-10-02
CR20190546A (es) 2020-04-08
AU2022241471A1 (en) 2022-10-27
SG10202111623TA (en) 2021-12-30
BR112019022483A2 (pt) 2020-05-12
GEAP202416602A (en) 2024-10-10
US20240189261A1 (en) 2024-06-13
AU2018260666B2 (en) 2022-07-21
MX2022010349A (es) 2022-09-19
MX394941B (es) 2025-03-24
JP2023139000A (ja) 2023-10-03
GEP20247617B (en) 2024-04-25
JP7373997B2 (ja) 2023-11-06
US20200054583A1 (en) 2020-02-20
US20240261239A1 (en) 2024-08-08
AU2018260666A1 (en) 2019-11-14
KR20190140019A (ko) 2019-12-18
NZ758564A (en) 2023-12-22
WO2018200775A1 (en) 2018-11-01
MX2019012729A (es) 2019-12-19
ECSP19084058A (es) 2020-01-31
SG11201909973UA (en) 2019-11-28
GEP20257788B (en) 2025-08-25
CO2019013180A2 (es) 2020-02-07
NI201900110A (es) 2020-03-18
DOP2019000274A (es) 2019-12-30
CN110799181A (zh) 2020-02-14
CA3061468A1 (en) 2018-11-01
PH12019502427A1 (en) 2020-10-05
UA127759C2 (uk) 2023-12-27
EP3615016A1 (en) 2020-03-04

Similar Documents

Publication Publication Date Title
KR102682159B1 (ko) 수면 무호흡을 치료하기 위한 방법 및 조성물
JP7422666B2 (ja) 睡眠時無呼吸を治療するための方法および組成物
JP7705348B2 (ja) 睡眠時無呼吸を治療するための方法および組成物
AU2022245235A1 (en) Methods and compositions for treating sleep apnea
HK40013951A (en) Methods and compositions for treating sleep apnea
OA19434A (en) Methods and compositions for treating sleep apnea.
EA048116B1 (ru) Способы и композиции для лечения синдрома обструктивного апноэ, возникающего во сне
HK40065333B (en) Methods and compositions for treating sleep apnea
HK40065333A (en) Methods and compositions for treating sleep apnea
EA045789B1 (ru) Способы и композиции для лечения апноэ во сне

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601